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Abstract 1
In the absence of any ideal gene delivery carrier despite the recent explosion of novel 2 carrier systems, the current trend is to explore the complementary synergy promised by a 3 combination of delivery systems such as liposomes, which are the most widely 4 researched versatile non-viral carriers and tissue-engineered scaffolds with 5 macrostructures of defined architecture comprised of natural or synthetic macromolecules. 6
Here, we discuss the recent advances in liposomal gene delivery and the possible benefits 7 of a combined liposome-scaffold approach, such as long-term expression, enhanced 8 stability, reduction in toxicity and ability to produce spatio-temporal expression patterns. 9
This approach is generating significant impact in the field due to its potential for 10 extended localised gene delivery for applications in a variety of clinical conditions. 11 12 13 Gene Delivery Systems 14 The bottleneck in the success of gene therapy has been the development of a safe and 15 efficient gene delivery system 1 . Viral carriers are on one end of the spectrum, with very 16 high transfection efficiency, but also the potential risks of toxicity or immunogenicity, in 17 addition to their other disadvantages, such as difficulty of large scale production and 18 limited capacity to carry DNA beyond a certain size. Naked plasmid DNA is on the other 19 end of the spectrum, exhibiting a very attractive safety profile, but extremely low 20 efficiency. Non-viral carriers, which include liposomes and polymers, lie in middle of the 21 spectrum with a moderate efficiency and safety profile. Research in the field of delivery 22 systems over the past few decades has focused mainly on the development of an optimal 23 delivery system, aiming to increase transfection efficiency towards the viral end of the 1 spectrum, while reducing toxicity to exhibit a superior safety profile and reduce 2 immunological concerns. This review focuses on non-viral carriers, which due to their 3 superior safety profile and their broad acceptance have been considered as reliable 4 treatment options for a wide variety of medical indications and we will provide a 5 snapshot of the versatility of liposomes as the most widely researched non-viral carriers. 6
We will also highlight recent progress in the field, including crucial modifications to the 7 liposomal formulations, which have enabled them to overcome major barriers in systemic 8 delivery or intracellular obstacles to improve their efficiency of gene delivery. 9 10 Another focus of this review is tissue-engineered scaffolds. These are being widely used 11 as control release systems to deliver drugs, cells and/or bioactive agents, such as growth 12 factors and genes. These slow-release systems can lengthen gene expression without risk 13 of insertional mutagenesis as is the case in some of the viral carriers. However, the 14 delivery of plasmid DNA from tissue-engineered scaffolds still poses the problem of low 15 efficiency. Given the lack of a single superior delivery system that addresses all clinical 16 requirements with high efficacy and a convincing safety profile, an increasing amount of 17 research in recent years has focused on improving the delivery systems through a 18 combinatorial approach, whereby each component complements the others and thus 19 might lead to an optimized outcome. 20
21
In conclusion, we will illustrate how the combinatorial approach of using liposomal 22 systems together with tissue-engineered scaffolds has been employed and has lead to 23 synergistic effects in three main areas of safety, efficiency and extended expression in a 1 variety of applications and highlight future trends and the promising potential for clinical 2 translation. 3 4 Liposomes: multifaceted and versatile non-viral delivery systems 5
Liposomes are spherical lipid bilayers of diameters in the range of 50 1000 nm that have 6 proven useful as convenient delivery vehicles for biologically active compounds 2 . 7
Liposomal systems, despite being the oldest of the non-viral gene-delivery vehicles, still 8 remain attractive amid a surge of newer non-viral gene carriers. Their persisting 9 popularity is not only due to advantages, such as their unlimited load carrying capacity, 10 relative safety and ease of large-scale production, but can also be attributed to their 11 versatile nature in terms of possible functionalization and formulations. Despite the lower 12 transfection rates of conventional liposomal systems (typically requiring 1,000 to 10,000 13 times more particles to achieve successful genetic modification of cells compared with 14 viral counterparts), their potential for targeted delivery through functionalisation, for 15 example by conjugation with antibody (or fragments), peptides, sugars and so-called 16 .e. polyethylene glycol (PEG)-ylation of lipids, and for escape from the 17 reticuloendothelial system (RES) and, consequently, long-term circulation has proven to 18 be a great advantage. Early progress during the 1970s and 1980s has lead to the 19 development of 20 administration and decreased uptake by macrophages. These stealth liposomes are able to 21 extravasate out of vasculature and to accumulate in other target tissues, such as lung, 22 kidney and liver, in therapeutically effective doses without rapid clearance from the 23 blood stream, thus improving their bio-distribution 3 . Moreover, liposomes can be labeled 1 with fluorescent tags for traceability in vivo. A variety of stimuli, such as pH, temperature, 2 ultrasonic waves, magnetic fields and light are currently being investigated for improved 3 gene delivery in various settings 4-7 . In Tables 1 and 2, we list only the recent, major 4 advances in gene delivery applications (for more extensive and complete versions, the 5 readers are referred to the online supplementary material). Co-application of liposomes 6 with other polymers such as polyethyleneimine provides an avenue for improved 7 transfection efficiency 8-10 . 8 9
Successful liposomal gene delivery: stumbling blocks and solutions 10
There are a number of extracellular and intracellular barriers to successful non-viral gene 11 delivery. In systemic delivery, serum instability and sequestration by the RES due to 12 uptake by macrophages are major problems. Various factors such as size, charge and 13 surface hydration of the liposomes play important roles here. Cellular membranes pose 14 another barrier to liposome uptake. The cationic liposomes show high transfection 15 efficiency, which can partly be attributed to interactions with negatively charged cell 16 membranes. The structure and properties of cationic lipids, lipoplex (see Glossary) 17 assembly and endocytosis of lipoplexes have recently been described in detail 11 . The 18 internalisation of liposomes occurs most commonly by endocytosis, in which the genetic 19 material is subjected to degradation upon acidification in endolysosomes. Thus, the 20 efficiency of liposome uptake largely depends on their ability to escape the endosomal 21 environment and to deliver their DNA/RNA content safely into the cytosol. This is also 22 the reason why many research efforts have been directed towards enhancing endosomal 23 escape. Transfection efficiencies can be predicted from the structural phases of lipids and 1 the morphologies of lipoplexes. For example, studies have shown that the presence of a 2 non-bilayer-phase-preferring lipid, such as dioleoylphosphatidylethanolamine (DOPE) or 3 cholesterol, promotes transition of liquid crystalline phase (L C ) to inverted hexagonal 4 phase (H C II ) and hence membrane fusion, indicating that increasing the weight fraction of 5 DOPE might result in higher transfection efficiencies 12 . 6 7 Peptides for intracellular delivery 8
Recently, peptides have been increasingly used with the aim to aid the intracellular 9 delivery of the genes. Tat peptide (TATp) is by far the most commonly used cell 10 penetrating peptide, or so-called protein transduction domain (PTD), and is derived from 11 the transcriptional activator protein encoded by human immunodeficiency virus type 1 12 (HIV-1). Its mechanism has recently been elucidated as macropinocytosis, a nonclathrin 13 noncaveolar endocytosis brought about by formation of large vacuoles that are generated 14 by actin filaments 13 . TATp-mediated delivery of liposomes and DNA has recently been 15 reviewed 13, 14 . Octaarginine is another commonly used PTD that is thought to use cell 16 surface heparin sulfate proteoglycans as non-specific receptors for uptake. Octaarginine-17 modified liposomes have been used for enhanced cellular uptake and controlled 18 intracellular trafficking of plasmid DNA 15 . Apart from cell penetration, peptides are also 19 being utilized for endosomal escape, which in turn results in higher transfection 20 efficiency. Another cell-penetrating peptide is GALA, (a 30-amino acid synthetic peptide 21 with a glutamic acid alanine leucine alanine repeats), a fusogenic pH-sensitive peptide 22 developed by Szoka and co-workers that aids cytosolic delivery by facilitating the 23 disruption of endosomal membrane and release of DNA in cytoplasm. Kobayashi et al. 1 and Sasaki et al. demonstrated enhanced endosomal escape of macromolecules via 2 GALA and its derivatives 16, 17 . While fusogenic peptides act upon acidification in 3 endosomes, it has been recently shown that a stearylated INF7 peptide derivative 4 enhanced gene expression in a fusion-independent manner and was able to rupture 5 artificial membranes, both at acidic and neutral pH, extending the time the liposomes 6 could escape endosomal degradation 18 . Once successful delivery of liposomes to the 7 cytosol has been accomplished, liposome-mediated gene delivery faces additional 8 obstacles, such as the requirement of intracellular trafficking to the nucleus and uptake 9 into the nucleus via the nuclear pore complexes. The potential of using nuclear 10 localisation signals (NLSs) for targeting to the nucleus has been studied by several 11 groups and it was found that the efficiency of nuclear targeting depended on the valency 12 (positive charges) associated with plasmid DNA and the number of NLS associated with 13 a cargo, such as plasmid DNA, proteins, liposomes and nanoparticles 19 . Different NLSs 14 will bind to different receptors on nuclear membranes, such as to importins 20 or farnesoid 15 X receptor (FXR) 21 , either directly or indirectly by forming complexes with other 16 cytoplasmic proteins. A significant increase in gene expression that was mediated by 17 liposomes and the means of using a NLS has been shown, both in vitro and in vivo 20, 21 . 18 Attempts have also been made to utilize the biological responses against liposomes, such 19 as cytokine production, for their increased uptake. Tumor necrosis factor--20 21 reported that if NF-ex-1 mediated transgene expression can be enhanced 22 . 2 3 Short term expression and toxicity related to liposomes 4 Short-term expression following liposomal gene delivery constitutes a major problem in 5 clinical applications that require sustained levels of transgene expression over months 6 and years. Short-term expression is due to the cargo being either not integrated into the 7 host genome, or only unstably, and this limitation can be addressed with repeated doses 8 of the gene, a practice, which however is not always feasible and practical. Here, gene 9 delivery via release systems with an extended effect, such as tissue-engineered scaffolds, 10 presents the opportunity of controlled DNA release over a long period of time as required 11 for long-term expression. The toxicity of cationic lipids is another concern as these are 12 frequently inflammatory. This toxicity is dose-dependent and is based on to the exposure 13 of the liposome to and its interactions with immune cells. The use of tissue-engineered 14 scaffolds could address these issues as a topical delivery of liposomes via a tissue 15 scaffold would reduce their exposure to immune cells. 16 17
Tissue-Engineered Scaffolds 18
The view of tissue-engineered scaffolds as gene delivery systems is a relatively novel 19 concept. Initially, scaffolds were proposed for applications in tissue engineering and 20 considered solely as inert structural support for tissue repair and regeneration. Over the 21 last few years, this view has changed dramatically and scaffolds are no longer seen only 22 as dynamic tools for mimicking biological environments, but now are also regarded as 23 delivery vehicles for cells and/or bioactive agents. They provide a multitude of 1 advantages, such as safe profile, protection of cargo, and enhanced and extended gene 2 expression and the ability to control a localized delivery of cargo, as depicted in Figure 1 . 3 4 Tissue-engineered scaffolds as depots and controlled-release systems 5
Tissue-engineered scaffolds can be designed in order to physically and/or chemically 6 control the release pattern of any incorporated bioactive agents. A controlled release of 7 DNA will not only lead to extended periods of gene and thus protein expression, but will 8 also minimize the risk of under-or over-dosing of the expressed protein. The major 9 advantage of using natural scaffolds, such as collagen and fibrin, in addition to their 10 safety profile, is their tunable degradation, which can be readily achieved either by 11 varying the concentration of monomers and/or crosslinking agents and thus controls the 12 long-term release of bioactive agents. Similar to extracellular matrix (ECM), fibrin-based 13 biomaterials could also act as temporary depots for the sustained release of substances 23 As an alternative to natural scaffolds, synthetic scaffolds have also been suggested as 21 they are highly flexible in that they can be manufactured in any desired shape and size, 22 with a tightly defined architecture and relevant parameters such as porosity. Some of 23 these synthetic scaffolds, such as polylactic acid (PLA), also have the additional 1 advantage of a degradation within the body, which will only leave behind harmless 2 breakdown products such as lactic acid 1 . By crosslinking of PLA with PEG, or by using 3 co-polymers such as poly(lactic-co-glycolic acid) (PLGA), their degradation in the body 4 can be further controlled 1 . 5 6 Need for further enhancement 7
Although, as depicted in Figure 1 , the enhanced and sustained localized gene delivery 8 that could be achieved via tissue-engineered scaffolds is certainly superior to that of 9 naked plasmid delivery, further enhancement is required for therapeutic benefit. Towards 10 this goal and as opposed to delivering naked plasmid DNA through scaffolds, a number 11 of researchers have utilized different transfection reagents such as liposomes to first 12 complex the DNA and to subsequently deliver these complexes via the scaffolds, as 13 outlined below. 14
15
A combined liposome scaffold approach 16
As mentioned above, the combination of liposomal gene delivery systems with scaffold 17
technologies is now being considered as being complementary. Table 3 summarizes a 18 number of studies that have investigated tissue-engineered scaffold-mediated liposomal 19 gene delivery. The various aspects and intrinsic benefits offered by this combined 20 liposome-scaffold approach are discussed in detail below. 21
22
Long-term expression 23 By far the most important advantage of combining tissue-engineered scaffolds with 1 liposomal gene delivery is the possibility and flexibility of a well-controlled sustained 2 delivery. This allows to overcome an only short-term gene expression following 3 liposomal delivery, although the release kinetics of the used lipoplexes would depend on 4 various factors, such as their size and net charge, as well as their biomolecular and 5 chemical interactions. 6
The combination of tissue-engineered scaffolds with liposomes has already been utilized 7 for sustained delivery of drugs. For example, a single application of fibrin-enmeshed 8 tobramycin-bearing liposomes had a similar effect on reducing pseudomonas colonies 9 when treating pseudomonas keratitis compared to 24 hourly doses of fortified topical 10 tobramycin 25 . Subsequently, a number of studies have described sustained release 11 systems using liposomes loaded with proteins or drugs and that had been incorporated in 12 fibrin [26] [27] [28] [29] . The biomedical applications of collagen, including a combination of 13 liposomes with collagen for drug delivery, have been reviewed elsewhere 30 . 14 The extended release of lipoplexes, and consequently the long-term expression of their 15 delivered genes, has been demonstrated by a number of groups [31] [32] [33] [34] [35] . To achieve sustained 16 delivery, different approaches were possible. For example, lipoplexes could be merely 17 entrapped physically within the scaffolds by tailoring certain parameters, such as the 18 degree of crosslinking and pore sizes. Alternatively, lipoplexes were specifically bound 19 to components of the scaffolds. Recently, we described a fibrin-lipoplex system making 20 use of naturally-occurring interactions between liposomes and the fibrinogen components 21 of the scaffold, which obviated the need for chemical conjugation 32 . 22
Another approach for creating a sustained delivery system is the adsorption of lipoplexes 1 on the surface of scaffolds [36] [37] [38] . To facilitate lipoplex adsorption, scaffold surfaces have 2 been coated with various ECM proteins, and this has led to being able to transfect a 3 higher number of cells, while at the same time reducing the amount of DNA required. 4 Several other strategies have been developed to associate lipoplexes or DNA complexes 5 with the scaffold surface, including the specific binding of complexes to the scaffold 6 through biotin avidin interaction, gelatin entrapment, or by nonspecific adsorption 36 . 7 8 Maintaining lipoplex stability 9
Another major advantage of the combining liposomes with scaffolds is that this approach 10 maintains lipoplex stability with a consequently prolonged bioactivity. An increased 11 liposomal stability has been demonstrated in fibrin-encapsulated liposomes that were 12 used as protein delivery system 39 , as well as in biophysical studies of collagen-lipid 13 interactions 40 . The local delivery of lipoplexes from a biomaterial scaffold, such as 14 fibronectin-coated PLG, could have the ability to maintain lipoplex stability and therefore 15 could increase the number of transfected cells and transgene expression 34 . In a spinal cord 16 injury model, high transgene expression has been achieved by implanting fibronectin-17 coated-PLG bridges with multiple hollow channels that had been immobilised with 18 lipoplexes 34 . However, the fabrication of the scaffold can also adversely affect the 19 stability of lipoplexes. Therefore, special processing techniques, such as cryopreparation 20 or carbohydrate stabilization as well as mild processing conditions need to be adopted to 21 avoid any detrimental effect on lipoplex stability, and thus the activity of incorporated 22 DNA complexes 41 . On the other hand, if lipoplexes are immobilized on the surface of a 23 scaffold, the need for careful processing steps is obviated as the lipoplexes are 1 immobilised after the scaffold fabrication. 42 . 2 3
Moderating lipoplex toxicity 4
Although considered safer than viral delivery systems, lipoplexes are frequently 5 associated with some degree of toxicity, typically in the form of inflammatory responses. 6
The enhanced transgene expression observed via the combined liposome-scaffold 7 approach reduces the required dose and this indirectly reduces dose-related toxicity. 8
However, the cellular toxicity seen in direct bolus delivery of lipoplexes has been shown 9 to be reduced significantly when they are delivered via gene activated matrix (GAM) 31 . 10 This can be explained by the fact that, at any given time, only those lipoplexes that are 11 released from and that are only a fraction of the total amount incorporated in the scaffold, 12 13 reduce the observed toxicity of lipoplexes. Another postulation that can explain the 14 observed reduction in toxicity is that the specific interaction of cells with scaffold 15 material such as fibrin can lead to suppression of the caspase pathway, which is involved 16 in cell apoptosis and that of reactive oxygen species, which are typically activated by 17 liposomes 43 . Also, when compared to bolus delivery, this approach has been shown to 18 transfect cells, which are otherwise hard to transfect such as primary cells, and with 19 improved cellular viability 36 . Thus, with regard to toxicity, embedding the lipoplexes 20
within the scaffold appears a particular useful approach, whereas surface adsoption is 21 beneficial in terms of flexibility of fabrication and stability. In addition, the possibility of 22 a localised therapy as afforded by the use of scaffolds significantly reduces the 1 occurrence of systemic toxicity. 2 3 Multiple gene delivery and spatio-temporal patterning 4
Combining liposomes with scaffolds also provides several additional advantages, such as 5 the possibility to deliver multiple genes simultaneously 32 , or to create spatial 44 and 6 temporal patterns of gene delivery. Recently, we demonstrated the successful 7 simultaneous delivery of two reporter genes by means of a fibrin-lipoplex model system 8 32 . Such a system might prove particularly useful in diseases in which multiple genes are 9 involved, or in which the local restoration of a specific gene function can result in 10 therapeutic benefit, e.g. the compromised wound healing seen in diabetes mellitus. In 11 most tissues in the body, a highly orchestrated spatio-temporal control of gene expression 12 is established, particularly in neural and vascular networks. Recently, spatially-patterned 13 expression of nerve growth factor (NGF) was achieved using lipoplexes that had been 14 immobilised in microfluidic networks of polydimethylsiloxane (PDMS) and this 15 patterned expression of NGF led to neurite outgrowth and guidance 44 . Another means to 16 control spatial gene expression, is to immobilize lipoplexes to specific regions of the 17 scaffold, which is the basis for transfected cell-arrays used in high-throughput functional 18 genomics studies 38 . Here, patterned deposition of lipoplexes can be achieved by various 19 techniques, such as spotting, printing, pinning and microfluidics 45 . Additionally, temporal 20 control over gene expression can be achieved in a number of ways, such as by layer-by-21 layer assembly 46 of the scaffold with lipoplexes incorporated only in certain layers. Cell-22 controlled temporal expression patterns are also possible 43 , in which the lipoplexes are 23 confined within the scaffold, and only become available for transfection only upon cell-1 mediated degradation of scaffold. Another approach could be to simply mixing polymer 2 scaffolds that have different degradation profiles 45 or to fabricating a complex scaffold 3 consisting of predetermined regions with different degradation rates, different porosity or 4 different , such as antibodies or peptide ligands. The success 5 of spatial patterning depends largely on the stability and activity of DNA complexes after 6 they have been deposited on or embedded in the scaffold, and thus, the differential 7 concentration achieved on the pattern as against the non-patterned region of the scaffold 8
. 9
On the other hand, lipoplexes have also been shown to enhance the transfection 10 efficiency that can be achieved using only tissue-engineered scaffolds as demonstrated 11 for the delivery of lipoplexes based on fibrin-scaffolds based in skin wound healing 47 . 12
The authors of this study showed a significantly higher skin flap survival, when it was 13 treated with a fibrin-lipoplex system carrying vascular endothelial growth factor plasmid 14 (pVEGF) as compared to using a fibrin gel carrying pVEGF. The enhanced gene 15 expression upon liposome-scaffold delivery was synergistic and not merely additive. 16
Their claim could be substantiated by observations of six to seven-fold increase in 17 protein production compared to control levels as long as two weeks after treatment of rat 18 mesenchymal stem cells with a porous sponge-like collagen scaffold that had been 19 embedded with lipoplexes carrying glial cell line-derived neurotrophic factor (GDNF) 20 gene 48 . 21
22
Potential for clinical translation 23
One of the most promising aspects of combining liposome with scaffold-based delivery is 1 its potential for clinical translation in the near future. A range of tissue-engineered 2 scaffolds have already been approved for human use and this list is ever-increasing and 3 some relevant examples are summarized in Table 4 . Currently, over a hundred clinical 4 trials addressing liposomal gene delivery are underway and are at different phases of 5 completion. Considering the advantageous regulatory status of tissue-engineered 6 scaffolds and of liposomal approaches, a clinical realization of combined liposome-7 scaffold delivery could be anticipated within the next two decades. 8 9
Future perspectives 10
The full potential of a combined liposome-scaffold approach remains to be investigated 11 as research to date has mainly focused on providing proof of concepts. It is anticipated 12 that the future of a combined liposome-scaffold approach would be centered around two 13 goals: making optimal use of the progress in individual fields and the understanding 14 derived thereof, and utilizing and manipulating interactions between the liposomes and 15 the scaffold material as depicted in Figure 2 . 16
In particular, the versatility of liposomes has not yet been tested in the context of their 17 inclusion into tissue engineered-scaffolds. The recent advances in liposomal gene 18
delivery are yet to be applied in the combined approach. A recent study has already 19 pointed out the need for focusing research on designing lipoplexes with the aim to 20 increase the cellular internalization of DNA for enhancing gene delivery from scaffold 21 surface 49 . It is therefore highly likely that the successful application of combination 22 therapy will depend on advances in liposomal gene delivery with regard to targeted 23 delivery, enhanced intracellular trafficking and nuclear localization. The combined 1 2 such as stimuli-responsive polymers, or polymers that are cell interactive and based on 3 4 then compacted for ease of handling and for reaching the injury site, and upon 5 implantation would return to their original shape containing micropatterned lipoplexes. 6
This approach could be particular useful in areas of nerve regeneration, surgical sutures 50 7 and vascular stenting 51, 52 . In situ gelling systems with lower critical solution temperature 8 (see Glossary) at body temperature could be employed to carry lipoplexes, which after 9 application to wounds would form a gel scaffold and subsequently release lipoplexes in a 10 sustained manner. Also, research in the field of whole tissue organ regeneration can be 11 geared up through micropatterned lipoplexes in 3-D scaffolds for the creation of a highly 12 controlled spatio-temporal gene expression, mimicking the natural embryonic 13 
